Connect with us

Intended for US Healthcare Professionals Only.Important Safety Information

IXINITY delivers low clearance1

LOW CLEARANCE

FOR HEMOPHILIA B PATIENTS1

down icon
up icon

HIGH FACTOR IX LEVELS

FOR PATIENTS OVER TIME2

Man throwing a frisbee
caret left icon

Watch the LOW CLEARANCE. HIGH COVERAGE. video

See the data behind the low clearance and high coverage of IXINITY.
CTA icon

Connect with your local IXINITY Specialist and see if IXINITY is the right treatment for your patients.

*Phase 3 controlled, multicenter study of 76 patients designed to evaluate PK noninferiority of IXINITY to a comparator standard half-life rFIX, and to establish safety and hemostatic efficacy of IXINITY in previously treated adolescents and adults (≥12 years of age) with severe (FIX activity <1 IU/dL) and moderately severe (FIX activity ≤2 IU/dL) hemophilia B.1

FIX = factor IX; PK = pharmacokinetic; r = recombinant.

References: 1. IXINITY [coagulation factor IX (recombinant)]. Prescribing information. Chicago, IL: Medexus Pharma, Inc.; March 2024. 2. Data on file. Chicago, IL, Medexus Pharma, Inc. 3. Collins PW, Quon DVK, Makris M, et al. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia. 2018;24:104-112.

+ MORE

- LESS

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE: IXINITY® [coagulation factor IX (recombinant)] Lyophilized Powder for Solution for Intravenous Injection is a coagulation factor IX (recombinant) indicated in adults and children with hemophilia B for on-demand treatment and control of bleeding episodes, perioperative management, and for routine prophylaxis to reduce the frequency of bleeding episodes.

IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.

CONTRAINDICATIONS: IXINITY is contraindicated in patients who have known hypersensitivity to IXINITY or its excipients, including hamster protein.

WARNINGS AND PRECAUTIONS: Hypersensitivity reactions, including anaphylaxis, has occurred with IXINITY. Discontinue use of IXINITY if hypersensitivity symptoms occur, and initiate appropriate treatment. Regularly evaluate patients for the development of factor IX inhibitors by appropriate clinical observations and laboratory tests. If expected factor IX activity plasma levels are not attained, or, if bleeding is not controlled as expected with a certain dose, perform an assay that measures factor IX inhibitor concentration. An association between the occurrence of a factor IX inhibitor and allergic reactions has been reported. Individuals with factor IX inhibitors may be at increased risk of severe hypersensitivity reactions or anaphylaxis if re-challenged.

Nephrotic syndrome may occur with IXINITY. Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with factor IX inhibitors and a history of allergic reactions.

Thromboembolism has occurred with IXINITY (e.g., pulmonary embolism, venous thrombosis, and arterial thrombosis).

Patients may develop hypersensitivity to hamster (CHO) protein as IXINITY contains trace amounts.

The most common adverse drug reaction observed in >2% of patients in clinical trials was headache.

Please see full Prescribing Information.

You are encouraged to report adverse events related to Medexus Pharma products by calling 1-844-859-6675. If you prefer, you may contact the Food and Drug Administration directly. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information in this section is intended for healthcare providers in the United States. I certify that I am a healthcare provider in the United States.

Yes
No